Idioma:

Pharmacogenetics and pharmacogenomics of sexual dysfunction: current status, gaps and potential applications

Abdel-Hamid, Ibrahim A ; Andersson, Karl-Erik

Pharmacogenomics, 2009-10, Vol.10 (10), p.1625-1644 [Periódico revisado por pares]

England: Future Medicine Ltd

Texto completo disponível

Citações Citado por

Enviar para

Título:
Pharmacogenetics and pharmacogenomics of sexual dysfunction: current status, gaps and potential applications
Autor: Abdel-Hamid, Ibrahim A ; Andersson, Karl-Erik
Assuntos: androgens ; Clinical Trials as Topic ; Drug Design ; Female ; Genetic Variation ; Genomics - trends ; Genotype ; Guidelines as Topic ; Humans ; Male ; PDE5 inhibitors ; Pharmaceutical Preparations - administration & dosage ; pharmacogenetics ; Pharmacogenetics - trends ; pharmacogenomics ; phosphodiesterase-5 inhibitors ; Polymorphism, Genetic ; serotonin reuptake inhibitors ; sexual dysfunction ; Sexual Dysfunction, Physiological - genetics ; SSRIs ; Terminology as Topic
É parte de: Pharmacogenomics, 2009-10, Vol.10 (10), p.1625-1644
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Feature-3
ObjectType-Review-1
Descrição: Although treatment of different types of sexual dysfunction has improved in the past decade with the introduction of phosphodiesterase type 5 inhibitors and selective serotonin reuptake inhibitors, response rates to these targeted therapies are variable. There are a number of studies in the published literature that provide proof-of-concept that genetic variation contributes to the variable response. Pharmacogenomics will most likely be one part of our therapeutic armamentarium in the future and will provide a stronger scientific basis for optimizing drug therapy on the basis of each patient ’s genetic constitution. This article will review English language medical literature on the state-of-the-art genetic polymorphisms of drug targets, transporters and signaling molecules as well as pharmacogenetic studies of sexual dysfunction and suggested possible applications. Collectively, the data demonstrate that pharmacogenomics in the field of sexual medicine is still in its infancy. More research will provide further intriguing new discoveries in years to come.
Editor: England: Future Medicine Ltd
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Pharmacogenetics and pharmacogenomics of sexual dysfunction: current status, gaps and potential applications

Abdel-Hamid, Ibrahim A ; Andersson, Karl-Erik

England: Future Medicine Ltd

Buscando em bases de dados remotas. Favor aguardar.